<DOC>
	<DOCNO>NCT01116700</DOCNO>
	<brief_summary>Dexmedetomidine alpha-2 agonist commonly use neurosurgery due unique property sedative anxiolytic minimal respiratory depression . Neurosurgical patient frequently come operating room anticonvulsant therapy history seizure . The investigator clinical experience suggest patient resistant sedative effect dexmedetomidine . This effect may represent pharmacokinetic interaction anticonvulsant medication dexmedetomidine high dexmedetomidine dose requirement could result abnormal pharmacodynamics due underlying seizure disorder . The investigator study aim investigate pharmacokinetic pharmacodynamic difference dexmedetomidine patient receive receive enzyme-inducing anticonvulsant therapy identify potential mechanism difference .</brief_summary>
	<brief_title>Dexmedetomidine Seizure Patients</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Age 1865 , BMI 2025 kg/m2 Anticonvulsant Group : Diagnosis seizure disorder take carbamazepine phenytoin minimum 2 week Control Group : Healthy volunteer take medication Positive urine pregnancy test lactate History allergy dexmedetomidine alpha 2 agonist History liver , renal thyroid disease History cardiovascular disease include history arrhythmia congestive heart failure History drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Dexmedetomidine</keyword>
	<keyword>Seizure</keyword>
</DOC>